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Objective. Ovarian cancers are highly heterogeneous and while chemotherapy is the preferred treatment
many patients are intrinsically resistant or quickly develop resistance. Furthermore, all tumors that recur
ultimately become resistant. Recent evidence suggests that epigenetic deregulation may be a key factor in
the onset and maintenance of chemoresistance. We set out to identify epigenetically silenced genes that
affect chemoresistance.
Methods. The epigenomes of a total of 45 ovarian samples were analyzed to identify epigenetically
altered genes that segregate with platinum response, and further ﬁltered with expression data to identify
genes that were suppressed. A tissue culture carboplatin resistance screen was utilized to functionally
validate this set of candidate platinum resistance genes.Results. Our screen correctly identiﬁed 19 genes that when suppressed altered the chemoresistance of
the cells in culture. Of the genes identiﬁed in the screen we further characterized one gene, docking
protein 2 (DOK2), an adapter protein downstream of tyrosine kinase, to determine if we could elucidate
the mechanism by which it increased resistance. The loss of DOK2 decreased the level of apoptosis in
response to carboplatin. Furthermore, in cells with reduced DOK2, the level of anoikis was decreased.
Conclusions. We have developed a screening methodology that analyzes the epigenome and informatically
identiﬁes candidate genes followed by in vitro culture screening of the candidate genes. To validate our screening
methodology we further characterized one candidate gene, DOK2, and showed that loss of DOK2 induces
chemotherapy resistance by decreasing the level of apoptosis in response to treatment.© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
This year in the United States, more than 22,000 women will be
diagnosed with ovarian cancer, and 15,500 will die of this disease.dbury, NY, United States. Fax:
.
nc. Open access under CC BY-NC-ND licenseOvarian cancer is the leading cause of death from gynecologic cancer
and the ﬁfth most frequent cause of cancer-related death for women
in the United States. Despite signiﬁcant advances in surgical manage-
ment and chemotherapy in the past few decades, the survival rate for
ovarian cancer has not improved signiﬁcantly. Presently the standard
treatment is a platinum-based drug, such as carboplatin or cisplatin,
combined with taxol. Unfortunately, approximately 25% of patients
will present with primary platinum-resistant disease and will have
very poor outcomes. Additionally, all patients whose tumors recur will
ultimately develop acquired platinum resistance. At the heart of all
cancers lies alterations at the genome level. These alterations, genetic.
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the tumor, in some cases causing resistance to therapy. With recent
analyses by our group and also by The Cancer Genome Atlas (TCGA)
andothers [1–3]many commongenetic aberrations in ovarian carcinoma
have been identiﬁed, but the mechanism of therapy resistance is poorly
understood.
We have performed an epigenetic analysis of a set of primary
ovarian cancer samples. Epigenetic modiﬁcations such as CG dinucleo-
tide methylation can have far-reaching effects on cellular phenotypes,
such as chemotherapy resistance. We have used an array-based meth-
odology, Methylation Oligonucleotide Microarray Analysis (MOMA),
to analyze 45 ovarian samples with 6 refractory samples, 9 resistant
samples, 21 sensitive samples, and 9 normals. These data were then
analyzed to identify genes that were differentially methylated between
sensitive and resistant patients. Genes that were methylated and
exhibited suppressed expression in platinum-resistant patients were
identiﬁed. Since genes with acquired methylation in resistant patients
could be candidates for resistance to carboplatin, we performed further
function analysis of these genes. For these studieswedeveloped a tissue
culture platinum-resistance model. Three cell lines were selected with
varying response to carboplatin, from sensitive to resistant. Thus far
we have identiﬁed 19 genes in several different pathways that confer
resistance to carboplatin.
One gene, DOK2, has been further characterized to demonstrate its
ability to confer platinum resistance. We have shown that cells in
which DOK2 expression is suppressed are more resistant to platinum-
based drugs, such as carboplatin. We have also shown that the
increased resistance may be due to a change in the apoptotic response
system. Interestingly DOK2 is already known to be a tumor suppressor
in lung cancer, and our studies demonstrate that loss of DOK2 is
tumorigenic, thus indicating tumor suppressor activity of DOK2 in
ovarian cancer cells, as well.
Materials and Methods
Cell Lines and Reagents
Cell lines included HOSE 6–3 (obtained from Dr. S. W. Tsao [4]);
CAOV3 (ATCC# HTB-75); SKOV3 (ATCC# HTB-77); CAOV1 ovarian
adenocarcinoma cell lines; and 293 T packaging cell line (ATCC#
CRL-11268). MiR-30-lenti-based shRNA clones in a pGIPZ vector
(clone ID V2LHS_46643, V2LHS_46640, and V3LHS_367569), and
Arrest-in transfection reagent were obtained from Open Biosystems.
Retroviral shRNA clone in pSM2 vector (V2HS_46640) subcloned
into pMLP was obtained from Dr. L.V. Aelst. Virapower helper plas-
mid for lentiviral infection was obtained from Invitrogen. SYBR
Green, reverse transcriptase and RNase inhibitor were purchased
from Applied Biosystems. BSA was purchased through New England
Biolabs and bradford dye from Bio-Rad. Western blocking buffer was
ordered from Sigma. Caspase 3, γH2AX, and β-tubulin antibodies
were obtained from Cell Signaling. Transwell assays and reagents
were obtained from BD Bioscience. Carboplatin was purchased from
Sigma. Radioactive carboplatin was supplied by Accelerated Medical
Diagnostics. Primers were supplied by Sigma Genosys. NimbleGen
photoprint arrays and MTT assays were supplied by Roche. Design of
the array was described previously [5]. Datasets are available for
methylation (Data Series GSE27940 — http://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc=GSE27940) and expression (Affymetrix
GSE27943 - http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=
GSE27943) data are available from Gene Expression Omnibus.
Samples
Tumor DNA from 36 patients with advanced ovarian carcinomas
treated at the Memorial Sloan Kettering Cancer Center during the
period May 1992–February 2003 were included in this study. Thesamples were collected under an informed consent and IRB approval
[6]. Nine ovarian normal samples were obtained from The Cooperative
Human Tissue Network, a repository of tumor material run by the
National Institutes of Health.
Chemotherapy Sensitivity and Survival
The ovarian cell lines HOSE, SKOV-3, CAOV3 and CAOV1were tested
for IC20, IC50 and IC80 carboplatin sensitivity levels. Each cell line was
seeded at 103cells/well in a 96 well plate and treated with carboplatin
at a concentration range of 1–100 μg/ml in 100 μl of fully supplemented
DMEM. After a period of 72 h proliferation was assessed by MTT
3-(4.5-dimethylthiazol-2-yl)-2.5-diphenyl tetrazolium bromide assay
and absorbance measured at 595 nm using the Wallac microplate
reader (Perkin Elmer).
shRNA Screen
For each candidate gene, up to three miR30 shRNA clones in pLKO.1
and pGIPZ lentivirus vectors were selected from Open Biosystems Inc.,
propagated in bacteria and puriﬁed.
DNA from the virus pools were transfected into 293 T lentiviral
packaging cell lines using Arrest-in and Virapower helper plasmid. A
pool of GFP tagged pGIPZ empty vector was used to monitor transfec-
tion efﬁciencies. Efﬁciency of less than 70% was restarted (Fig. S1).
Lentiviral supernatants were harvested 48–72 h post-transfection for
infection of host cells. Cells were puro (2.5 μg/ml) selected followed
by carboplatin selection at the appropriate IC50 levels as previously
determined (Fig. S2) for a total of 3 cycles of 3 days on carboplatin,
3 days off (onward, referred to as 3 cycle selection). Cells were
harvested, genomic DNA isolated and the population of clones ampli-
ﬁed and sequenced for identity.
Viability Assay
Two sets of HOSE parental cell lines and HOSE shRNADOK2 cell lines
were plated at 5x10^4 cells/well in a volume of 500 μl of medium per
well in a 24-well plate in triplicate. The next day, one set of HOSE and
HOSE shRNA DOK2 was treated with carboplatin at the IC20, IC50, and
IC80 concentrations and the other set (without carboplatin) was used
as a control. After 3 days, cells were trypsinized and mixed in a 1:1
ratio with 0.4% trypan blue stain. The mixture was allowed to stand
for 2–3 min. Viable cells with no blue stain and dead cells with blue
stain were counted using a hemocytometer.
Anoikis Assay
Cell suspensions were plated at 1 × 10^4 cells/well at 100 μl per
well in a specialized 96-well anchorage resistant plate. Cells were
treated with carboplatin at the IC20, IC50, and IC80 concentration and
incubated at 37 °C for 3 days. A non-carboplatin treated set was
prepared as a control. 500X Calcein AM/EthD-1 stock was diluted to
100X with culture medium. 1 μl of the 100× working stock of Calcein
AM/EthD-1 was added to each well and incubated at 37 °C for
30–60 min. The cells were quantitatively measured using a ﬂuorescent
microplate reader at Ex: 485 nm and Em: 515 nm to measure viable
cells with Calcein AM or at Ex: 525 nm and Em: 590 nm to detect
dead cells with EthD-1.
Immunoblotting
Protein lysates were extracted from HOSE and HOSE shDOK2 cell
lines. A staurosporine treated HOSE cell line and UV control were
used as control sets. Protein concentrations were determined using
the Bradford Assay according to instructions, using BSA as standard
to determine lysate concentrations. Western blots were performed
Fig. 1. Heatmap of the differentially methylated genes from the MOMA analysis show-
ing segregation between the platinum therapy resistant and sensitive patient groups.
This heatmap presents the results from the MOMA analysis. Hierarchical clustering
was performed on the differentially methylated values from 749 probes that distin-
guished refractory/resistant and late sensitive patients. For these probes, hierarchical
clustering using Pearson correlation as a distance metric was used. The distance metric
is: 1- Pearson Correlation (x). The Ward method was utilized for ﬁnding clusters.
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using the Invitrogen E-Page® system. After transfer of lysates from
gel to PVDF membrane, blots were blocked and hybridized to Caspase
3 and γH2AX anti-bodies diluted 1:1,000 overnight. Membranes were
washed in TBS-Tween at room temperature. A ﬂuorescently labeled
anti-rabbit secondary antibody was diluted 1:10,000 and incubated
for 30–60 min. Membranes were washed and protected from light.
The odyssey infrared system was used to detect protein signals.
Anti-rabbit monoclonal β-tubulin was used as a loading control.
Transwell Invasion Assay
A 24-well plate with transwell inserts coated with Matrigel was
used as an invasion chamber. Cells were serum starved for a period of
16 h prior to the start of the invasion assay. Cell suspensions (500 μl;
1 × 105/ml) in serum-free medium were added to the inserts. 750 μl
of DMEM with 15% FBS were placed in the lower wells as a
chemoattractant and incubated for 24 h. Cells that had invaded to
lower surface of the Matrigel-coated membrane were ﬁxed with 4%
methanol in PBS, stained with 1:1 dilution of crystal violet, and counted
in ﬁve random ﬁelds using a brightﬁeld microscope. The number of
invading cells was quantiﬁed and normalized to mock-transfected
controls.
Results
Methylation Detection
For our methylation study, we selected 36 stage III or IV ovarian
serous carcinoma samples that had accurate clinical annotation for
platinum resistance, survival data for up to 10 years and also had associ-
ated expression data (Table S1). These samples were analyzed for meth-
ylation content using a previously developed method, Methylation
Oligonucleotide Microarray Analysis (MOMA) [7], an array-based
approach utilizing custom designed 380 K feature arrays that allowed
tiling coverage of 26,219 out of 27,801 (HG17) annotated CpG islands.
The association with the promoter was deﬁned by the distance of any
region of the island to the transcription start site. For this study we
concerned ourselves mainly with promoter islands, whose genetic loci
were within 2000 bp of the transcription start site. Geometric mean
values are obtained for the CpG island probes of two dye-swap hybrid-
izations from each sample.
Epigenetic Differences in Platinum Sensitivity
To identify genes involved in carboplatin resistance, we identiﬁed
methylated regions that segregated with platinum sensitivity. We
deﬁned resistance according to the platinum free interval, the period
between the last day of platinum treatment to the day of tumor recur-
rence. Patients tumors were grouped as refractory (tumors continued
to grow or progress during treatment), resistance (tumors responded
but recurred before 6 months), early sensitive (tumors recurred be-
tween 6 and 24 months), and late sensitive (tumors recurred after
24 months). We assayed 36 tumor and 9 normal samples with MOMA
array technology. We removed the heterogeneous early sensitive
group (n = 9) from the chemoresistance analysis, leaving only the
refractory/resistant samples (n = 15) and late sensitive (n = 12)
patient categories.
To identify the probes that best differentiated resistant from sensi-
tive samples, we performed Limma analysis using R/Bioconductor.
Our rationale was that Limma analysis would be more adequate due
to small number of available samples and very high number of micro-
array probes. Signiﬁcance analysis was performed using the moderated
t-statistic, which is computed for each probe between resistant and
sensitive patient data (P b 0.05). To increase stringency and identify a
set of probes that would more accurately segregate tumors basedon carboplatin sensitivity, we performed a leave-one-out analysis
(P b 0.05). In each round, we left out a single sample and performed
Limma test, and in the end kept only the probes that were statistically
signiﬁcant in all the 27 rounds when a single sample is left out. From
this analysis we identiﬁed 749 probes whose methylation was signiﬁ-
cantly different between resistant and sensitive patients (Table S2).
Fig. 1 presents the heatmap of the 749 differentially methylated probes
showing the segregation of the resistant and sensitive patient groups.
Since this analysis is based on the comparison of sensitive to resistant
there are regions found more frequently methylated in resistant or
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tant and 40% methylated in sensitive tumors.
Associating Methylation and Expression
For regions that differentiate between resistance and sensitivity,
we next determined, which methylation event potentially represses
transcription. For probes that were classiﬁed as being promoter CpG
island probes, we performed in parallel differential methylation and
differential expression analysis. Limma analysis and T-tests were done
for each dataset to identify the most signiﬁcant features (methylation
probes or Affymetrix probe sets respectively) using a p-value of 0.05
as a cutoff. We then combined themethylation and expression datasets
to determine which genes changed in methylation status with a
corresponding expression change (whether increased or decreased).
Of the original 749 probes that were statistically signiﬁcant for
methylation between resistant and sensitive patients, 509 were from
promoters. After probes from the same gene were removed and
remaining genes were matched to the Affymetrix U133A arrays used
for the expression data, 296 signiﬁcant genes were assessed for correla-
tion between methylation and expression.
In Vitro Platinum Screen
It was unclear if the gene candidates identiﬁed functionally altered
platinum resistance in the cell. Thus we next tested the candidate
genes in an in vitro carboplatin resistance assay. HOSE 6–3 (onward,
will be referred to as HOSE), SKOV3, and CAOV3 cell lines were selected
to perform functional studies. HOSE is a normal human ovarian surface
epithelial cell line that has been immortalized by introduction of the
HPV E6/7 ORF. This cell line has been previously used in the study of
chemoresistance ([8–10]) and has been found to be very sensitive to
carboplatin treatment. CAOV3 and SKOV3 are epithelial ovarian cancer
cell lines and show a moderate to high resistance to carboplatin
respectively.
We were most interested in genes that were methylated and
transcriptionally repressed in platinum resistant patients. In total
we identiﬁed approximately 296 gene candidates (Table S3). The
suppression of transcription caused by methylation was modeled by
the introduction of an shRNA clone. Since we had a large number ofTable 1
Single validation candidate genes.
Gene Gene Description Differential methyla
GSK3B Glycogen Synthase Kinase 3 Beta 0.011
DOK2 Docking Protein 2 0.013
APRT Adenine Phosphoribosyltransferase 0.046
OXSR1 Oxidative-stress Responsive 1 0.024
CENPB Major Centromere Autoantigen B 0.009
FZD1 Frizzled 1 0.015
ESRRA Estrogen-related Receptor Alpha 0.022
HIRIP3 HIRA Interacting Protein 3 0.035
GTF2b General Transcription Factor IIB 0.009
SGPL1 Sphingosine-1-phosphate Lyase 1 0.013
GABPA GA Binding Protein Transcription Factor, Alpha 0.028
TWIST1 Transcription Factor 0.036
MDH1 Malate Dehydrogenase 1B, NAD (soluble) 0.038
NR2E1 Nuclear Receptor Subfamily 2, Group E, Member 1 0.053
NR3C2 Nuclear Receptor Subfamily 3, Group C, Member 2 0.017
SOX9 Transcription Factor 0.041
TOB1 Transducer of ERBB2, 1 0.017
UNG Uracil-DNA Glycosylase Isoform UNG1 Precursor 0.012
ZIC1 Zinc Finger Protein of the Cerebellum 1 0.044
This table represents the genes that survived the pooled shRNA carboplatin screen at IC50.
selection of platinum drugs at the IC20, IC50 and IC80 concentrations. Results of the singl
differential expression p-values. Candidate genes for the pooled screen were selected based
data is included for reference. For certain methylation probes, expression data was not avacandidates, we used a pooling strategy for the introduction of the
shRNAs into the cells. By using 50 genes/pool (up to three shRNA
clones per gene) 6 pools of shRNAs were assayed.
This ﬁrst screen decreased the number of candidate genes by
approximately 75%. To be more conﬁdent of the candidates, each
shRNA clone was individually veriﬁed for carboplatin resistance using
three concentrations of carboplatin, the IC20, the IC50, and the IC80.
After the 3 cycle selection, we identiﬁed 19 positive hits (Table 1).Suppression of DOK2 Increases Platinum Resistance
Among the genes identiﬁed, to further validate our screeningmeth-
odology, we selected DOK2 for further functional characterization.
DOK2 has already been identiﬁed as a tumor suppressor in lung cancer
([11]) and its expression is suppressed in a number of other tumors
([12–15]). Cells infected with DOK2 shRNAs were assayed by qPCR to
ensure efﬁcient knockdown of DOK2 expression levels (Fig. S3). We
went on to study the effect of DOK2 suppression on carboplatin
resistance using cells with shRNA suppression of DOK2.
DOK2 suppression in cell lines resulted in a survival advantage with
platinum treatment at the IC20, IC50, and IC80 with the 3 cycle selec-
tion protocol (Figs. 2 and S4). As it is a tumor suppressor, suppression
of DOK2 may increase carboplatin resistance by increasing cell growth
and increasing the number of cells surviving treatment. To address this
concern, growth assays were done over the course of 9 days without
the addition of carboplatin, demonstrating that suppression of DOK2
in HOSE, SKOV3, and CAOV1 cell lines had little effect on the number
of cells growing (Fig. 3A–C). A 3-day Bromodeoxyuridine (BrdU)
assay was also used to measure the level of actively dividing cells.
Although the BrdU assay exhibited a slight selective growth advan-
tage for DOK2 knockdowns compared to their parental counterparts
in the HOSE and SKOV3 cell lines, it was not statistically signiﬁcant
(Fig. 3D). We therefore concluded that increased resistance to
carboplatin by suppression of DOK2 is a result of some other
mechanism other than increased growth of cells. It is important to
note that although the CAOV3 cell line was used for the initial
resistance screen, it was problematic for our functional studies
because of a change in morphology after frequent passages. We
therefore switched to a cell line exhibiting a similar level of sensitiv-
ity to carboplatin, CAOV1 (Fig. S2).tion p-value Differential gene expression p-value IC 20 IC 50 IC 80
N/A + + +
N/A + + +
0.188 + + −
0.808 + + −
0.862 + + −
0.508 + + +
0.464 + − −
N/A + + −
N/A + + −
0.651 + + −
N/A + + −
0.651 + + +
0.277 + + +
N/A + + −
N/A + + −
0.808 + + +
N/A + + +
0.277 + + −
0.917 + + +
Each gene was singly validated with one shRNA clone per gene and underwent 3 cycle
e gene validation for each dose are presented along with differential methylation and
on signiﬁcant p-values from the differential methylation data. Differential expression
ilable (N/A).
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Fig. 2. Knockdown of DOK2 increases platinum resistance in ovarian cell lines. Cell lines (A) HOSE (B) SKOV3 and (C) CAOV1 demonstrated suppression of DOK2 with lentivirus
increased resistance to carboplatin at the IC20, IC50, and IC80 concentrations after 9 days. Cells were plated at a density of 1x10^3 cells/well in 96-well plates in triplicate.
The IC concentrations on the x-axis is plotted against percentage survival on the y-axis. The results represent the mean ± SD (n = 6; P b 0.05) in triplicate.
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An alternative role for DOK2 in carboplatin resistance could be an
effect on apoptosis. The deregulation of the apoptotic pathway is
often shown to be involved in resistance [16–18], and this process
can be derailed by epigenetic mechanisms [19]. To determine
whether deregulating apoptosis is a mechanism of DOK2-mediated
carboplatin resistance, we plated HOSE parental and HOSE shRNA
DOK2 cell lines with and without carboplatin. After 3 days, the per-
cent viable cells to dead cells were determined using the crude and
simple but very effective method of trypan blue stain exclusion from
live cells. The results showed fewer dead cells in the shRNA DOK2HOSE
HOSEshDOK2
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Fig. 3. DOK2 silencing causes minimal effect on growth. A growth assay was also done ove
(A) HOSE, (B) SKOV3, and (C) CAOV1 causes little change in growth compared to their pare
The x-axis represents the time in days and the y-axis represents the cell count. The results r
sure actively proliferating cells was done using HOSE and SKOV3 parental and lentiviral c
6x10^3 cells/well in 96-well plates in triplicate. The x-axis represents the time in days an
P b 0.05) in triplicate.cell line compared to the parental HOSE cell line in the presence of
carboplatin (Fig. 4A). To determine if any earlier marks of apoptosis
such as levels of activated caspase 3 and γH2AX phosphorylation,
are affected by the loss of DOK2, western blots were performed
to detect activated caspase 3 and γH2AX phosphorylation after
carboplatin treatment in cells with and without DOK2. We found
decreased levels of activated caspase 3 and γH2AX phosphorylation
in cells with suppression ofDOK2 agreeingwith our results from trypan
blue exclusion (Fig. S5). Cells with DOK2 suppression had less cell death
and a subdued apoptotic response. These results suggest that aberrant
apoptosis signals are a factor in how suppression of DOK2 confers
resistance to carboplatin.SKOV3
SKOV3shDOK2Ce
ll C
ou
nt
Day 0 Day 3 Day 6 Day 9
70000
60000
50000
40000
30000
20000
10000
0
Ce
ll C
ou
nt
Day 0 Day 1 Day 2 Day 3
12000
11000
10000
9000
8000
7000
6000
5000
HOSE
HOSEshDOK2
SKOV3
SKOV3shDOK2
r the course of 9 days showing that lentiviral DOK2 shRNA infected ovarian cell lines,
ntal counterparts. Cells were plated at 1x10^3 cells/well in 96-well plates in triplicate.
epresent the mean ± SD (n = 6; P b 0.05) in triplicate. (D) 3-day BrdU assay to mea-
ell lines demonstrating a slight increase with DOK2 suppression. Cells were plated at
d the y-axis represents the cell count. The results represent the mean ± SD (n = 4;
A B
Pe
rc
en
ta
ge
IC Concentrations
Pe
rc
en
ta
ge
IC Concentrations
HOSE
HOSEshDOK2
Poly. (HOSE)
Poly.
(HOSEshDOK2)
HOSE
HOSEshDOK2
Linear (HOSE)
Linear
(HOSEshDOK2)
80
60
40
806040
20
20
0
8060402000
30
20
10
0
Fig. 4. DOK2 silencing results in decreased apoptosis/anoikis induced cell death. (A) HOSE parental and HOSEshDOK2 were plated in triplicate on a 24 well plate at 5 × 10^4 cells/
well and treated with carboplatin at the IC20, IC50, and IC80. Live/dead cells were measured with tryphan blue stain. The IC concentrations on the x-axis is plotted against percent-
age apoptotic on the y-axis. More dead cells were observed in the parental line in the presence of carboplatin. The results represent the mean ± SD (n = 2; P b 0.05) in triplicate.
(B) HOSE parental and HOSEshDOK2were plated in triplicate on a 96-well low binding plate at 1 × 10^4 cells/well and treated with carboplatin at the IC20, IC50, and IC80. Live cells
were stained with the calcein AM and dead cells were stained with EthD-1 and the ﬂuorescence signals were quantitatively measured using a ﬂuorescence plate reader. The IC
concentrations on the x-axis is plotted against percentage anoikis cells on the y-axis. A decrease in percentage of cell death was observed with loss of DOK2. The results represent
the mean ± SD (n = 2; P b 0.05) in triplicate.
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cellular matrix, a specialized form of programmed cell death termed
anoikis occurs to maintain tissue homeostasis and proper balance of
cell differentiation [20,21]. However, anoikis resistance can interfere
with this process and lead to the peritoneal dissemination of gastric
and ovarian cancer cells [22]. We wanted to further explore whether
the observed decreased cell death in the DOK2 knockdown was due
to protection from anoikis. We repeated the viability assay on low-
binding tissue culture plates, using calcein AM dye to detect viable
cells and ethium homodimer (EthD-1) to measure anoikis induced
cell death. A noticeable difference was observed in the percentage of
dead cells between parental and DOK2 suppressed cells when examin-
ing for anoikis (Fig. 4B).
DOK2 Silencing Confers an Invasive and Tumorigenic Phenotype In Vitro
In addition to its role in affecting apoptosis to confer carboplatin
resistance, DOK2 is also a known tumor suppressor in lung cancer
[11]. However, its role in ovarian cancer has not been established. We
therefore decided to explore whether DOK2 displayed tumor suppres-
sor features in ovarian cancer in culture. To measure tumorigenicity,
we ﬁrst assayed whether cell lines harboring the shRNA to DOK2 re-
quired a basement membrane, and performed experiments for growth
in soft agar [23,24]. DOK2 shRNA lentiviral and retroviral cells were
grown in soft agar for 3 weeks along with parental cell lines. DOK2
suppression increased colony growth (Fig. S5). In addition, to measure
invasive potential of the cells, a Matrigel assay was used to model the
effects through a basement membrane. After 24 h there was a marked
increase in the number of cells invading when DOK2 was suppressed
(Fig. 5). Scratch assays were also performed to evaluate migratory
potential. Little migration was observed with parental cell lines whileA
HOSE SKOV3 CAOV1
HOSEshDOK2 SKOV3shDOK2 CAOV1shDOK2
Fig. 5. Suppression of DOK2 showed increased invasive potential. (A) The matrigel invasion
5 × 10^4 cells/ml of serum starved cell suspensions. The bottom chamber was ﬁlled with m
increase of invading cells through the matrigel. (B) Quantiﬁcation of cell count showed suppr
increased invasive properties. Counts were based on an average cell count of 5 random areas
represent the mean ± SD (n = 6; P b 0.05) in triplicate.increased migration was observed for cells with DOK2 knockdown
(Fig. S6). Our results suggest that in ovarian cancer cells, a decrease
in the level of DOK2 is associated with tumor suppressive features,
such as increased invasiveness and tumorigenicity.
Since suppression of DOK2 has tumor suppressive features in ovarian
cell lines we next assessed if alteration of DOK2 had an effect on clinical
outcome by performing in silico analysis of public databases.We utilized
the cBioPortal for Cancer Genomics (http://www.cbioportal.org/public-
portal/) to determine ﬁrst if DOK2 alteration was found in patients
ovarian tumors and if there was a signiﬁcant difference in survival for
these patients. Survival is a complex clinical variable affected by
numerous parameters, gene alteration being only one of them. Using
the whole tumor dataset there was no signiﬁcant inﬂuence of DOK2
alteration on survival but if the patients with a complete response to
platinum treatment were selected (276 patients) DOK2 alteration was
signiﬁcant in both overall survival (p-value of 0.031334) as well as
disease free survival (p-value of 0.018653) (Fig. S8 Panels A and B
respectively). Furthermore if only homozygous deletions were assessed
for signiﬁcant affect on survival the p-value was even stronger
(0.001515 for overall survival and 0.000675 for disease free survival,
data not shown) but only 4 samples had DOK2 alteration. These data
suggests alteration of DOK2 has a signiﬁcant effect on survival likely to
be exerted by its effect on treatment response and/or tumor suppressive
activity.
Discussion
Chemo-resistance in ovarian cancer, as in many other cancers, is
an important clinical issue. The genome alterations that are respon-
sible for a tumor’s ability to resist treatment are often caused by ge-
netic mutations or epigenetic alterations. While others have lookedHOSE
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sponse, we have looked at the epigenome to determine whether
genes suppressed by DNA methylation have a role in therapy resis-
tance. We utilized a three step screening methodology to identify
candidate genes that were involved in chemo-resistance. First, we
used genome wide screening to identify epigenetic alterations that
occur in ovarian tumors. Next, we used informatics and statistical
methods to identify alterations that could segregate resistant from
sensitive patients. Lastly, we utilized an in vitro cell culture shRNA
screen to identify genes that when epigenetically suppressed increased
platinum resistance.
The clustering of the epigenetic and informatics screening results
segregated the samples along carboplatin resistance, based on Limma
analysis, showing that among the 749 identiﬁed candidate probes
there is a difference in methylation patterns between the resistant
and sensitive patients. Since oncogenesis may not be a prerequisite to
chemotherapy resistance, it was not surprising that we did not identify
a large number of tumor suppressors and oncogenes (data not shown).
A number of well-characterized genes were identiﬁed that have been
linked to resistance, such as PTEN and HIF1 [25–28].
Our informatics screen deﬁned a list of candidate genes that were
assayed with our in vitro carboplatin shRNA tissue culture screen. Of
the positive hits from the screening, there were a number of notable
genes, including SOX9, ZIC1, TWIST (involved in EMT) [29–35], GSK3B
and FZD1 (both involved in WNT signaling) [36,37]. The screen
successfully validated that some of the genes identiﬁed with epigenetic
alterations could affect carboplatin sensitivity in the cells. To further
validate the screen, we went on to characterize the cellular mechanism
altered by the DOK2 proteins that led to carboplatin resistance.
One major path of resistance involves deregulating apoptosis. Dys-
functional apoptotic responses may result in uncontrolled cell growth,
leading to cancer [38]. The effectiveness of most chemotherapies, such
as platinum therapy relies heavily on their ability to induce apoptosis.
As a consequence, chemo-resistant cells often have down-regulated
pro-apoptotic genes or up-regulated anti-apoptotic genes. In addition
to key regulators in the apoptotic pathway, DNA methylation of gene
targets has also been shown to affect various mechanisms of therapy,
including membrane transport, drug metabolism, DNA repair, and
apoptosis [19].
In ovarian cancer, intraperitoneal ﬂuid accumulates resulting in a
buildup of non-adherent cancerous ascites cells [39]. Tumor cells in
ascitesmust bypass suspension-induced apoptosis, or anoikis, to spread
to distant organs [22]. DOK2, in addition to decreasing the level of
classical apoptosis, could also suppress the level of anoikis. We propose
that suppression of DOK2 gives ovarian tumor cells a selective advan-
tage in becoming chemotherapy resistant non-adherent tumor cells in
ascites. Suppression of anoikis has been reported to promotemetastasis
and resistance to chemotherapy in certain cancers, including breast and
ovarian cancers [40].
The link between anoikis resistance with anchorage independency
and metastasis [41] prompted us to test whether suppression of
DOK2, in addition to suppressing anoikis, also increased a tumorigenic
phenotype. Indeed the loss of DOK2 induced a tumorigenic phenotype
in ovarian cell lines. We propose that loss of contact inhibition and
increased invasive properties observed in DOK2 suppressed cells,
while being typical hallmarks of cancer cells, are key components of
anoikis suppression, as well.
Our lab has developed a chemo-resistance screen to identify what
epigenetic changes occurred in primary ovarian tumor samples and
has characterized which of these functionally alter carboplatin resis-
tance. Recent evidence ﬁnding some serous ovarian cancers are likely
to originate from fallopian tubes rather than ovarian epithelia raises
questions for the analysis of DOK2. In the future, it will be useful to uti-
lize both an immortalized ovarian and fallopian tube epithelial cell lines.
However this recent data concerning the cell of origin for EOC does not
affect the selection of genes for our screen, since all of our analysisrevolved around the comparison of tumor to tumor for both methyl-
ation and expression. One gene found methylated, DOK2, was select-
ed and we demonstrated that suppression of this gene increases
carboplatin resistance by decreasing both classical apoptosis and the
non-adherent form of apoptosis, anoikis, a mechanism that is critical
to ovarian cancers progression by ascites associated metastasis. We
also show that suppression of DOK2, a known tumor suppressor in
lung cancer, appears to have tumor suppressor features in ovarian
cancer as well. These results validate our approach to ﬁnding genes
epigenetically regulated that are involved in chemo-resistant ovarian
cancer. We have made our results publicly available in the Gene
Expression Omnibus database for the ovarian cancer community (see
materials and methods). Understanding the molecular events that
lead to chemotherapy resistance will allow us to develop more suitable
chemotherapy regimens, learn how to re-sensitize cells to current
drugs, and improve current drug designs or invent novel therapeutics.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.ygyno.2013.05.002.
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